Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
HANGZHOU, CHINA, Jan 12, 2022 – (ACN Newswire via SEAPRWire.com) – On January 8, AIM Vaccine held a meeting at Shulan (Hangzhou) Hospital to report on the analysis results of […]